Latest from Incanthera
ICT01 – patent granted in Japan
Incanthera receives the official Patent Certificate from the Japan Patent Office, confirming protection for ICT01 in Japan.
The Company’s most advanced programme, ICT01, focuses on the development of a new anticancer agent, which has been dubbed a ‘smart bomb’. ICT01 releases a warhead when in contact with an enzyme specifically released by a cancer. Preclinical in vitro and in vivo data are very encouraging and the company is preparing ICT01 for a Phase I clinical trial.
The Company has secured patent protection in Japan. Protection has been confirmed and the company has received the Patent Certificate, issued by the Japanese Patent Office.
Confirming protection in Japan for our ICT01 programme is very important to the company and its commercial ambitions. This patent offers exclusivity in this very important market. We have now secured two very important markets, the US and Japan. We believe our continuous effort to bring novel anticancer agents to the clinic will offer improved treatment options.